Eine Studie zur Bewertung der Wirksamkeit und Sicherheit von Icotrokinra (JNJ-77242113) bei biologisch erfahrenen Teilnehmern mit aktiver psoriatischer Arthritis (ICONIC-PsA 2)
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie, die die Wirksamkeit und Sicherheit von JNJ-77242113 zur Behandlung von biologisch erleichterten Teilnehmern mit aktiver Psoriasis-Arthritis bewertet
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Buenos Aires, Argentinien, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentinien, C1406AGA
- ARCIS Salud SRL Aprillus asistencia e investigacion
-
Buenos Aires, Argentinien, C1426
- Hospital Militar Central Cir. My. Dr. Cosme Argerich
-
Ciudad de Buenos Aires, Argentinien, C1431
- Arsema
-
Ciudad de San Miguel de Tucuman, Argentinien, T4000AXL
- Centro Medico Privado de Reumatologia Tucuman
-
San Fernando, Argentinien, B1646GHP
- MR Medicina Reumatologica
-
-
-
-
-
Ipswich, Australien, 4305
- Ipswich Hospital
-
Maroochydore, Australien, 4558
- Rheumatology Research Unit
-
South Woodville, Australien, 5011
- Queen Elizabeth Hospital
-
St Leonards, Australien, 2065
- Royal North Shore Hospital
-
Tiwi, Australien, 0810
- Royal Darwin Hospital
-
-
-
-
-
Belo Horizonte, Brasilien, 30130 100
- Faculdade de Medicina Universidade Federal de Minas Gerais
-
Porto Alegre, Brasilien, 90480 000
- LMK Servicos Medicos S S
-
São José do Rio Preto, Brasilien, 15090-000
- Funfarme Sjrp
-
São Paulo, Brasilien, 05403 900
- Hospital Das Clinicas Da Faculdade De Medicina Da USP
-
São Paulo, Brasilien, 01236030
- BR Trials
-
São Paulo, Brasilien, 04266 010
- CEPIC Centro Paulista de Investigacao Clinica e Servicos Medicos
-
-
-
-
-
Plovdiv, Bulgarien, 4003
- Multiprofile Hospital for Active Treatment Plovdiv
-
Plovdiv, Bulgarien, 4001
- UMHAT Kaspela
-
Sliven, Bulgarien, 8801
- Diagnostic Consulting Center I Sliven
-
Sofia, Bulgarien, 1431
- Diagnostic-Consultative Center (DCC) Aleksandrovska
-
Sofia, Bulgarien, 1336
- Multiprofile Hospital for Active Treatment - MHAT Lyulin EAD
-
Sofia, Bulgarien, 1612
- UMHAT St. Ivan Rilski
-
Sofia, Bulgarien, 1750
- ASIMP Rheumatology Centre St Irina EOOD
-
Sofia, Bulgarien, 1407
- MC Ekselsior
-
-
-
-
-
Beijing, China, 100083
- Peking University Third Hospital
-
Beijing, China, 100730
- Beijing Tong Ren Hospital Capital Medical University
-
Changchun, China, 130021
- The First Bethune Hospital of Jilin University
-
Changsha, China, 410008
- Xiangya Hospital Central South University
-
Chengdu, China, 610041
- West China Hospital Sichuan University
-
Chengdu, China, 610072
- Sichuan Provincial Peoples Hospital
-
Chongqing, China, 400016
- The First Affiliated Hospital of Chongqing Medical University
-
Dongguan, China, 523109
- Dongguan People s Hospital
-
Guangzhou, China, 510515
- Nanfang Hospital of Southern Medical Hospital
-
Guiyang, China, 550004
- The Affiliated Hospital of Guizhou Medical University
-
Hangzhou, China, 310018
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Jiaxing, China, 314001
- The First Hospital of Jiaxing
-
Jinhua, China, 321000
- Jinhua municipal central hospital
-
Linfen, China, 041000
- Linfen Central Hospital
-
Linyi, China, 276002
- Linyi City People Hospital
-
Nanchang, China, 330008
- The Second Affiliated Hospital of Nanchang University
-
Nantong, China, 226001
- Affiliated Hospital of Nantong University
-
Pingxiang, China, 337055
- Pingxiang People's Hospital
-
Shanghai, China, 200040
- Huashan Hospital Fudan University
-
Shanghai, China, 200443
- Shanghai skin disease hospital
-
Shenzhen, China, 518020
- Shenzhen People s Hospital
-
Suzhou, China, 215004
- Second Affiliated Hospital of Soochow University
-
Taiyuan, China, 030032
- Shanxi Bethune Hospital
-
Wenzhou, China, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Xi'an, China, 710006
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
Berlin, Deutschland, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Berlin, Deutschland, 10117
- Charite - Campus Mitte
-
Cologne, Deutschland, 51149
- Krankenhaus Porz am Rhein
-
Dresden, Deutschland, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Freiburg im Breisgau, Deutschland, 79106
- Medizinische Fakultaet Der Albert Ludwigs Universitaet Freiburg
-
Hamburg, Deutschland, 20095
- Hamburger Rheuma Forschungszentrum II
-
Herne, Deutschland, 44649
- Rheumazentrum Ruhrgebiet
-
Langenau, Deutschland, 89129
- Praxis Dr. med. Beate Schwarz - Germany
-
Ratingen, Deutschland, 40878
- Rheumaforschung - Studienambulanz Dr. Wassenberg
-
Tübingen, Deutschland, 72076
- Universitatsklinikum Tubingen
-
-
-
-
-
Aarhus N, Dänemark, 8200
- Aarhus University Hospital
-
Esbjerg, Dänemark, 6700
- Sydvestjysk Sygehus
-
Frederiksberg, Dänemark, 2000
- Frederiksberg Hospital
-
Herning, Dänemark, 7400
- Regionshospitalet Godstrup
-
Svendborg, Dänemark, 5700
- Svendborg Hospital Odense University Hospital
-
Vejle, Dänemark, 7100
- Vejle Sygehus
-
-
-
-
-
Hong Kong, Hongkong
- Queen Mary Hospital
-
Hong Kong, Hongkong, 000000
- Prince of Wales Hospital
-
-
-
-
-
Ahmedabad, Indien, 380060
- Marengo Cims Hospital
-
Bhubaneswar, Indien, 751005
- Apollo Hospitals
-
Hubballi, Indien, 580021
- Sushruta Multispeciality Hospital
-
Kolkata, Indien, 700054
- Apollo Multispeciality Hospital Ltd
-
Mysuru, Indien, 570004
- JSS Hospital
-
New Delhi, Indien, 110029
- All India Institute of Medical Sciences
-
New Delhi, Indien, 1100776
- Indraprastha Apollo Hospital
-
Noida, Indien, 201301
- Fortis Hospital
-
Surat, Indien, 395002
- SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre
-
-
-
-
-
Ancona, Italien, 60126
- A.O. Universitaria Ospedali Riuniti di Ancona
-
Brescia, Italien, 25123
- ASST Spedali Civili Brescia
-
Catania, Italien, 95124
- Policlinico San Marco
-
Milan, Italien, 20132
- Ospedale San Raffaele
-
Naples, Italien, 80138
- Azienda Ospedaliero Universitaria Luigi Vanvitelli
-
Pavia, Italien, 27100
- IRCCS Policlinico San Matteo
-
Roma, Italien, 00133
- Universita Degli Studi di Roma Tor Vergata
-
Roma, Italien, 00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italien, 20089
- Istituto Clinico Humanitas
-
Siena, Italien, 53100
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
Udine, Italien, 33100
- Ospedale S. Maria Della Misericordia
-
-
-
-
-
Chiba, Japan, 260-8712
- NHO Chiba Medical Center Chibahigashi National Hospital
-
Chūōku, Japan, 104 8560
- St. Luke's International Hospital
-
Hirakata, Japan, 573 1191
- Kansai Medical University Hospital
-
Hyōgo, Japan, 6751392
- Kita-harima Medical Center
-
Kitakyushu-shi, Japan, 807-8556
- Hospital of the University of Occupational and Environmental Health
-
Nagoya, Japan, 467 8602
- Nagoya City University Hospital
-
Osaka, Japan, 550 0006
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
-
Osaka, Japan, 545 8586
- Osaka Metropolitan University Hospital
-
Sanuki, Japan, 7692393
- Sanuki Municipal Hospital
-
Sasebo, Japan, 857 1195
- Sasebo Chuo Hospital
-
Sendai, Japan, 980 8574
- Tohoku University Hospital
-
Shimotsuga Gun, Japan, 321 0293
- Dokkyo Medical University Hospital
-
Tokyo, Japan, 181 8611
- Kyorin University Hospital
-
Tsu, Japan, 514 8507
- Mie University Hospital
-
Yokohama, Japan, 245-8575
- National Hospital Organization Yokohama Medical Center
-
Ōita, Japan, 870 0030
- Maeshima Rheumatology Clinic
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1C 5B8
- Eastern Regional Health Authority St Clares Mercy Hospital
-
-
Ontario
-
Orillia, Ontario, Kanada, L3V 1T5
- The Waterside Clinic
-
Toronto, Ontario, Kanada, M5S 1B1
- Womens College Hospital
-
Waterloo, Ontario, Kanada, N2J 1C4
- Alliance Clinical Trials
-
Windsor, Ontario, Kanada, N8X 1T3
- Dr Sabeen Anwar Medicine Professional Corporation
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 2M4
- Hospital Maisonneuve-Rosemont
-
Trois-Rivières, Quebec, Kanada, G9A 3X2
- Centre de Recherche Musculo Squelettique
-
-
-
-
-
Alor Star, Malaysia, 05460
- Hospital Sultanah Bahiyah
-
Batu Caves, Malaysia, 68100
- Hospital Selayang
-
Ipoh, Malaysia, 30450
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, Malaysia, 81100
- Hospital Sultan Ismail
-
Kuala Lumpur, Malaysia, 50586
- Hospital Kuala Lumpur
-
Seremban, Malaysia, 70300
- Hospital Tuanku Jaafar
-
-
-
-
-
Culiacán, Mexiko, 80000
- Centro de Investigacion de Tratamientos Innovadores de Sinaloa
-
Guadalajara, Mexiko, 44630
- Grupo Clinico CATEI
-
Mexicali, Mexiko, 45116
- Centro Medico del Angel
-
Mexico City, Mexiko, 03100
- RM Pharma Specialists
-
Monterrey, Mexiko, 64460
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
San Luis Potosí City, Mexiko, 78213
- Centro de Alta Especialidad en Reumatologia e Investigacion
-
-
-
-
-
Bialystok, Polen, 15-879
- ClinicMed Daniluk Nowak Spolka Komandytowa
-
Bialystok, Polen, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Bialystok, Polen, 15-375
- Specderm Poznanska sp j
-
Bydgoszcz, Polen, 85-168
- Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
-
Elblag, Polen, 82-300
- Centrum Kliniczno Badawcze
-
Elblag, Polen, 82-300
- Ambulatorium sp. z o.o.
-
Gdynia, Polen, 81-338
- Centrum Medyczne Pratia Gdynia
-
Krakow, Polen, 30-727
- Pratia MCM Krakow
-
Krakow, Polen, 30-002
- Malopolskie Badania Kliniczne Sp z o o
-
Krakow, Polen, 30-002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Krakow, Polen, 30-033
- Centrum Medyczne All Med
-
Lodz, Polen, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Lublin, Polen, 20-607
- Zespol Poradni Specjalistycznych Reumed Filia nr 1
-
Nadarzyn, Polen, 05-830
- NZOZ Lecznica MAK MED S C
-
Torun, Polen, 87-100
- MICS Centrum Medyczne Torun
-
Warsaw, Polen, 00-874
- MICS Centrum Medyczne Warszawa
-
Warsaw, Polen, 02-665
- Centrum Medyczne Reuma Park
-
Wroclaw, Polen, 52-416
- Centrum Medyczne Oporow
-
Wroclaw, Polen, 51-503
- DermMedica Sp z o o
-
-
-
-
-
Bucharest, Rumänien, 014142
- S C Delta Health Care S R L
-
Bucharest, Rumänien, 012071
- Quantum Medical Center Srl
-
Bucharest, Rumänien, 030463
- CCBR Clinical Research
-
Bucharest, Rumänien, 041312
- Hiperdia Piata Sudului
-
Craiova, Rumänien, 200400
- Ecomed Research SRL
-
Iași, Rumänien, 700259
- Centrul Medical Unirea
-
Râmnicu Vâlcea, Rumänien, 247065
- Medaudio Optica S R L
-
-
-
-
-
A Coruña, Spanien, 15006
- Hosp Univ A Coruna
-
Córdoba, Spanien, 14004
- Hosp Reina Sofia
-
L'Hospitalet de Llobregat, Spanien, 08907
- Hosp. Univ. de Bellvitge
-
Madrid, Spanien, 28031
- Hosp. Univ. Infanta Leonor
-
Málaga, Spanien, 29009
- Hosp Regional Univ de Malaga
-
Santander, Spanien, 39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela, Spanien, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Spanien, 41013
- Hosp. Virgen Del Rocio
-
Seville, Spanien, 41009
- Hosp. Virgen Macarena
-
Seville, Spanien, 41014
- Hosp. Ntra. Sra. de Valme
-
Seville, Spanien, 41010
- Hosp. Infanta Luisa
-
-
-
-
-
Hsinchu, Taiwan, 300
- National Taiwan University Hospital Hsin Chu Branch
-
Kaohsiung City, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Tainan, Taiwan, 710
- Chi Mei Medical Center
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital
-
-
-
-
-
Bangkok, Thailand, 10400
- Phramongkutklao Hospital
-
Bangkok, Thailand, 10700
- Siriraj Hospital
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
Changwat Sara Buri, Thailand, 18000
- Saraburi Hospital
-
Songkhla, Thailand, 90110
- Songklanagarind hospital
-
-
-
-
-
Brno, Tschechien, 63800
- Revmatologie s r o
-
Brno, Tschechien, 615 00
- Revmacentrum MUDr Mostera s r o
-
Břeclav, Tschechien, 690 02
- RHEUMA s r o
-
Hlučín, Tschechien, 748 01
- L K N Arthrocentrum
-
Ostrava, Tschechien, 70200
- CCR Ostrava S R O
-
Ostrava, Tschechien, 708 00
- MUDr Rosypalova s r o
-
Prague, Tschechien, 13000
- Pratia Czech s r o
-
Prague, Tschechien, 15000
- FN Motol
-
Uherské Hradiště, Tschechien, 68601
- Medical Plus S R O
-
Zlín, Tschechien, 76001
- PV Medical S R O
-
-
-
-
-
Ankara, Türkei (türkiye), 06010
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara, Türkei (türkiye), 06570
- Gazi Universitesi Tip Fakultesi
-
Gaziantep, Türkei (türkiye), 27090
- Sanko Universitesi Hastanesi
-
Istanbul, Türkei (türkiye), 34899
- Marmara University Medical Faculty
-
Kocaeli, Türkei (türkiye), 41001
- Kocaeli University Medical Faculty
-
Konya, Türkei (türkiye), 42080
- Necmettin Erbakan Universitesi Tip Fakultesi
-
-
-
-
-
Budapest, Ungarn, 1152
- Uno Medical Trials Ltd.
-
Budapest, Ungarn, 1023
- Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
-
Budapest, Ungarn, 1027
- Revita Kft
-
Budapest, Ungarn, 1134
- Qualiclinic Kft
-
Békéscsaba, Ungarn, 5600
- Trial Pharma Kft
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Reumatologiai Klinika
-
Gyula, Ungarn, 5700
- Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
-
Hódmezővásárhely, Ungarn, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Ungarn, 7400
- Obudai Egeszsegugyi Centrum Kft
-
Kecskemét, Ungarn, 6000
- Bacs Kiskun Varmegyei Oktatokorhaz
-
Szeged, Ungarn, 6725
- University of Szeged
-
Szolnok, Ungarn, 5000
- MAV Korhaz es Rendelointezet
-
Székesfehérvár, Ungarn, 8000
- Complex Rendelo Med Zrt
-
Székesfehérvár, Ungarn, 8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
-
Veszprém, Ungarn, 8200
- Vital Medical Center Orvosi es Fogaszati Kozpont
-
-
-
-
Arizona
-
Glendale, Arizona, Vereinigte Staaten, 85306
- AARA Clinical Research
-
Mesa, Arizona, Vereinigte Staaten, 85210
- AARA Clinical Research 1
-
-
Arkansas
-
Jonesboro, Arkansas, Vereinigte Staaten, 72401
- Arthritis and Rheumatism Associates ARA Jonesboro
-
-
Florida
-
Clearwater, Florida, Vereinigte Staaten, 33765
- Clinical Research of West Florida
-
DeBary, Florida, Vereinigte Staaten, 32713
- Omega Research Consultants
-
New Port Richey, Florida, Vereinigte Staaten, 34652
- Suncoast Clinical Research
-
Plantation, Florida, Vereinigte Staaten, 33324
- Integral Rheumatology And Immunology Specialists
-
Tampa, Florida, Vereinigte Staaten, 33606
- Clinical Research of West Florida 1
-
-
Illinois
-
Skokie, Illinois, Vereinigte Staaten, 60076
- Clinic of Robert Hozman
-
-
Maryland
-
Hagerstown, Maryland, Vereinigte Staaten, 21740
- Klein And Associates M D P A
-
-
Massachusetts
-
Brookline, Massachusetts, Vereinigte Staaten, 02446
- DM Clinical Research 1
-
-
Minnesota
-
Eagan, Minnesota, Vereinigte Staaten, 55123
- St Paul Rheumatology PA
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87102
- Albuquerque Rehabilitation and Rheumatology
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Joint and Muscle Research Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73116
- Rheumatology Associates of Oklahoma
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Vereinigte Staaten, 16635
- Altoona Center For Clinical Research
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19114
- Clinical Research Philadelphia
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern
-
Frisco, Texas, Vereinigte Staaten, 75035
- Arthritis and Rheumatology Research Institute
-
Harlingen, Texas, Vereinigte Staaten, 78550
- Naiara Alvarez MD Integrative Rheumatology of South TX
-
Irving, Texas, Vereinigte Staaten, 75039
- AARA Clinical Research Lone Star Arthritis and Rheumatology
-
Tomball, Texas, Vereinigte Staaten, 77375
- DM Clinical Research
-
Waco, Texas, Vereinigte Staaten, 76710
- Velocity Clinical Research
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Seattle Rheumatology
-
-
Wisconsin
-
Glendale, Wisconsin, Vereinigte Staaten, 53217
- Center of Rheumatic Diseases
-
-
-
-
-
Barnet, Vereinigtes Königreich, EN5 3DJ
- Royal Free London NHS Foundation Trust
-
Basingstoke, Vereinigtes Königreich, RG24 9NA
- Basingstoke And North Hampshire Hospital
-
Christchurch, Vereinigtes Königreich, BH23 2JX
- University Hospitals Dorset NHS Foundation Trust
-
Edinburgh, Vereinigtes Königreich, EH4 2XU
- Western General Hospital
-
Glasgow, Vereinigtes Königreich, G31 2ER
- Glasgow Royal Infirmary
-
Hereford, Vereinigtes Königreich, HR1 2ER
- Hereford County Hospital
-
Larbert, Vereinigtes Königreich, FK5 4WR
- Forth Valley Royal Hospital
-
Staffordshire, Vereinigtes Königreich, ST6 7AG
- Haywood Hospital
-
Torquay, Vereinigtes Königreich, TQ2 7AA
- Torbay Hospital-Devon
-
Wolverhampton, Vereinigtes Königreich, WV10 0QP
- New Cross Hospital
-
Wrexham, Vereinigtes Königreich, LL13 7TD
- Betsi Cadwaladr University Health Board BCUHB
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Have active psoriatic arthritis (PsA) despite current or previous use of greater than or equal to (>=) 1 of the following: a. Non-biologic disease-modifying antirheumatic drug (DMARD) therapy; b. Apremilast therapy; c. Biologic-agent (limited to only 1)
- Have a diagnosis of PsA for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
- Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) >= 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
- Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
- Have active plaque psoriasis with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with psoriasis
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Exclusion Criteria:
- Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances
- Currently has a malignancy or has a history of malignancy within 5 years prior to screening
- Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients
- Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or Lyme disease
- Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group I: Icotrokinra Dose 1
Participants will receive icotrokinra Dose 1. Participants who have not discontinued will be eligible to enter a long term extension (LTE) and will continue to receive icotrokinra Dose 1. |
Icotrokinra will be administered.
Andere Namen:
|
|
Experimental: Group II: Icotrokinra Dose 2
Participants will receive icotrokinra Dose 2. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 2. |
Icotrokinra will be administered.
Andere Namen:
|
|
Placebo-Komparator: Group III: Placebo
Participants will receive placebo matched to icotrokinra and will cross over to receive icotrokinra Dose 1 or Dose 2 at Week 16. Participants who have not discontinued will be eligible to enter a LTE and will continue to receive icotrokinra Dose 1 or Dose 2. |
Placebo will be administered. Icotrokinra will be administered.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
Zeitfenster: Week 16
|
The ACR 20 responders are participants with an improvement of greater than or equal to (>=) 20 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale (VAS), patient's global assessment of disease activity [arthritis, VAS] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein). |
Week 16
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants Who Achieved Psoriatic Area and Severity Index (PASI) 75 Response at Week 16 Among Participants with Baseline Body Surface Area (BSA) Greater Than Equal to (>=) 3 Percent (%) and With Baseline IGA Score of >=2
Zeitfenster: Week 16
|
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants who achieved at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
Proportion of Participants Who Achieved PASI 90 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Zeitfenster: Week 16
|
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
Proportion of Participants Who Achieved PASI 100 Response at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Zeitfenster: Week 16
|
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants who achieved at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
Proportion of Participants with an Investigator Global Assessment (IGA) Psoriasis Score of 0 or 1 And >=2 Grade Improvement From Baseline at Week 16 Among Participants with Baseline BSA >=3% and With Baseline IGA Score of >=2
Zeitfenster: Week 16
|
Proportion of participants with an IGA psoriasis score of 0 or 1 And >=2 grade improvement from baseline at Week 16 among participants with >=3% BSA and an IGA Score of >=2 at Baseline will be reported. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling, each using a 5-point scale: using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema, and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants who Achieved an ACR 50 Response at Week 16
Zeitfenster: Week 16
|
The ACR 50 responders are participants with an improvement of >= 50% from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain VAS, patient's global assessment of disease activity (arthritis, VAS) scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein). |
Week 16
|
|
Proportion of Participants who Achieved an ACR 70 Response at Week 16
Zeitfenster: Week 16
|
The ACR 70 responders are participants with an improvement of >= 70% from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain VAS, patient's global assessment of disease activity (arthritis, VAS) scale, Physician's global assessment of disease activity VAS scale, health assessment questionnaire and C-reactive protein). |
Week 16
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score At Week 16
Zeitfenster: From baseline up to Week 16
|
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Responses in each functional area are scored from 0 to 3 (0=no difficulty and 3=inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
From baseline up to Week 16
|
|
Changes From Baseline in 36 Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Zeitfenster: From baseline up to Week 16
|
SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a domain was an average of the individual question scores, which were scaled 0 to 100 (100=highest level of functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100=highest level of physical functioning). |
From baseline up to Week 16
|
|
Proportion of Participants With Resolution of Enthesitis at Week 16 Among Those With Enthesitis at Baseline
Zeitfenster: Week 16
|
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). |
Week 16
|
|
Change From Baseline in Enthesitis Score at Week 16 in Participants With Enthesitis at Baseline
Zeitfenster: Baseline and Week 16
|
Enthesitis will be assessed using the LEI. The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). |
Baseline and Week 16
|
|
Proportion of Participants With Resolution of Dactylitis at Week 16 Among Those With Dactylitis at Baseline
Zeitfenster: Week 16
|
Dactylitis is characterized by swelling of the entire finger or toe. Presence and severity of dactylitis will be assessed in both hand and feet using a scoring system from 0 to 3 (0: no dactylitis, 1: mild dactylitis, 2: moderate dactylitis, 3: severe dactylitis). The result for each digit are summed to produce a final dactylitis score with a range from 0 to 60. Higher score indicates greater severity. |
Week 16
|
|
Change From Baseline in Dactylitis Score at Week 16 in Participants With Dactylitis at Baseline
Zeitfenster: From baseline up to Week 16
|
Dactylitis is characterized by swelling of the entire finger or toe. Presence and severity of dactylitis will be assessed in both hand and feet using a scoring system from 0 to 3 (0: no dactylitis, 1: mild dactylitis, 2: moderate dactylitis, 3: severe dactylitis). The result for each digit are summed to produce a final dactylitis score with a range from 0 to 60. Change from baseline in dactylitis score measure the change in dactylitis, where a negative change indicates an improvement and a positive change indicates a worsening. |
From baseline up to Week 16
|
|
Proportion of Participants who Achieved Minimal Disease Activity (MDA) at Week 16
Zeitfenster: Week 16
|
MDA criteria are a composite of 7 outcome measures used in PsA. Participants are classified as achieving MDA if they fulfill at least 5 out of the 7 outcome measures: tender joint count less than or equal to (<=) 1; swollen joint count <= 1; psoriasis activity and severity index <= 1 or body surface area <= 3 percent (%); patient pain VAS score of <= 15; patient global disease activity VAS (arthritis and psoriasis) score of <= 20; health assessment questionnaire (HAQ) score <= 0.5; and tender entheseal points <= 1. |
Week 16
|
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16
Zeitfenster: From baseline up to Week 16
|
The FACIT-fatigue is a self-administered, 13 item questionnaire measuring items on tiredness, weakness, and difficulty conducting usual activities due to fatigue. Responses to all items are rated on a 5-point Likert response scale ranging from 0 "not at all" to 4 "very much." The total score ranges from 0 to 52, with higher values indicating less fatigue. |
From baseline up to Week 16
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 77242113PSA3002
- 2024-517284-23-00 (Registrierungskennung: EUCT number)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .